Catalyst Biosciences Inc(CBIO)stock report

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Q3 2019(9/30/19): Cash 84.95M. Loss 12.71M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -2.68 64.03% 53.14%
2019.3.31 -1.26 -125.00% 52.99%
2019.6.30 -2.41 -119.09% 11.00%
2019.9.30 -3.47 -98.29% -43.98%



Insider Transactions:

Institution Ownership:
Total institutions: 58,no change
Shares hold: 7524k shares. no change
shares% hold: 62.49%,no change

Analyst Ratings:

Leave a Reply